FDA Approves Hadlima (adalimumab-bwwd), a Biosimilar to Humira

Article Link: FDA Approves Hadlima (adalimumab-bwwd), a Biosimilar to Humira

INCHEON, Korea – July 24, 2019 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Hadlima (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab)i, for the treatment of…

Source: FDA New Drug Approvals